<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184353</url>
  </required_header>
  <id_info>
    <org_study_id>173-03</org_study_id>
    <nct_id>NCT00184353</nct_id>
  </id_info>
  <brief_title>Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.</brief_title>
  <official_title>In Vivo Proton MR Spectroscopy of Brain Metastases Obtained at 1,5T and 3T.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Royal Norwegian Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing magnetic field is known to give improvements in signal-to-noise-ratio (SNR) and
      spectral resolution. To investigate this, spectra from different subjects were examined using
      two clinical MR instruments operating at 1.5T and 3T respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Neoplasm Metastases</condition>
  <arm_group>
    <arm_group_label>brain metastases</arm_group_label>
    <description>6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
    <description>13 volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with brain metastases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  brain metastases

        Exclusion Criteria:

          -  children

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steinar Lundgren, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Clinic, St.Olavs Hospital Trondheim University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid S Gribbestad, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Norwegian University of Science and Technology, Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norwegian University of Science and Technology</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7489</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Sj√∏bakk TE, Lundgren S, Kristoffersen A, Singstad T, Svarliaunet AJ, Sonnewald U, Gribbestad IS. Clinical 1H magnetic resonance spectroscopy of brain metastases at 1.5T and 3T. Acta Radiol. 2006 Jun;47(5):501-8.</citation>
    <PMID>16796315</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>October 20, 2011</last_update_submitted>
  <last_update_submitted_qc>October 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastasis</keyword>
  <keyword>signal to noise ratio</keyword>
  <keyword>spectral resolution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

